FDA reviews risk-benefit profile of certain oral contraceptives

The FDA launched a safety review of birth control pills that contain drospirenone, in light of two recent studies in the British Medical Journal concluding that such products cause a higher risk of blood clots than levonorgestrel-based contraceptives. The finding conflicts with some previous studies that also compared the synthetic hormones, the agency said. The FDA is "evaluating the conflicting results from these studies and will look at all currently available information to fully assess the risks and benefits of drospirenone."

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA